Gain Therapeutics, Inc. (NASDAQ:GANX) Sees Large Growth in Short Interest

Gain Therapeutics, Inc. (NASDAQ:GANX) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 2,976,352 shares, an increase of 19.9% from the January 15th total of 2,482,134 shares. Approximately 8.3% of the shares of the company are short sold. Based on an average daily volume of 795,383 shares, the short-interest ratio is presently 3.7 days. Based on an average daily volume of 795,383 shares, the short-interest ratio is presently 3.7 days. Approximately 8.3% of the shares of the company are short sold.

Gain Therapeutics Stock Performance

Shares of GANX stock opened at $1.83 on Thursday. Gain Therapeutics has a 52-week low of $1.41 and a 52-week high of $4.34. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. The stock has a market cap of $70.38 million, a PE ratio of -3.00 and a beta of 0.05. The business has a 50-day simple moving average of $2.45 and a 200-day simple moving average of $2.25.

Hedge Funds Weigh In On Gain Therapeutics

Institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new stake in shares of Gain Therapeutics during the 3rd quarter worth about $68,000. JPMorgan Chase & Co. purchased a new position in Gain Therapeutics during the third quarter worth approximately $47,000. Marshall Wace LLP grew its holdings in Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after purchasing an additional 80,407 shares during the period. Geode Capital Management LLC increased its position in shares of Gain Therapeutics by 2.9% in the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after buying an additional 8,251 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Gain Therapeutics during the 4th quarter worth approximately $45,000. 11.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on GANX shares. Roth Mkm reissued a “buy” rating and set a $10.00 price objective on shares of Gain Therapeutics in a report on Friday, December 19th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Friday, December 19th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Monday, December 29th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.